Rowlandmiller & PARTNERS.ADV Sells 95 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Rowlandmiller & PARTNERS.ADV decreased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 9.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 883 shares of the medical research company’s stock after selling 95 shares during the quarter. Rowlandmiller & PARTNERS.ADV’s holdings in Bio-Rad Laboratories were worth $295,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in BIO. Capital Advisors Ltd. LLC lifted its holdings in Bio-Rad Laboratories by 193.8% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 62 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after buying an additional 45 shares in the last quarter. Sound Income Strategies LLC acquired a new stake in shares of Bio-Rad Laboratories during the first quarter worth $38,000. EntryPoint Capital LLC acquired a new stake in shares of Bio-Rad Laboratories during the first quarter worth $51,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Bio-Rad Laboratories during the second quarter worth $51,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on BIO shares. Royal Bank of Canada reissued an “outperform” rating and set a $401.00 target price on shares of Bio-Rad Laboratories in a report on Friday, August 16th. Citigroup raised Bio-Rad Laboratories from a “neutral” rating to a “buy” rating and boosted their price target for the company from $350.00 to $400.00 in a research note on Tuesday, October 1st. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price target for the company. Finally, StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $368.20.

Bio-Rad Laboratories Price Performance

Shares of NYSE:BIO opened at $327.70 on Friday. The company has a quick ratio of 4.63, a current ratio of 6.28 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a twelve month low of $261.59 and a twelve month high of $364.24. The stock’s 50 day moving average is $331.48 and its 200-day moving average is $307.58. The firm has a market capitalization of $9.35 billion, a price-to-earnings ratio of -31.63 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, August 1st. The medical research company reported $3.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.99. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.73%. The business had revenue of $638.50 million during the quarter, compared to the consensus estimate of $645.79 million. During the same quarter in the prior year, the company posted $3.00 earnings per share. Bio-Rad Laboratories’s revenue was down 6.3% compared to the same quarter last year. Sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 9.45 EPS for the current fiscal year.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, COO Andrew J. Last sold 3,000 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the transaction, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP James Barry sold 623 shares of the stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the sale, the executive vice president now owns 147 shares of the company’s stock, valued at approximately $48,582.03. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Andrew J. Last sold 3,000 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the sale, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.